Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

被引：0

作者：

Von Minckwitz, Gunter

Hahnen, Eric

Fasching, Peter A.

Hauke, Jan

Schneeweiss, Andreas

Salat, Christoph

Rezai, Mandi

Blohmer, Jens U.

Zahm, Dirk Michael

Jackisch, Christian

Gerber, Bernd

Klare, Peter

Kummel, Sherko

Eidtmann, Holger

Paepke, Stefan

Nekljudova, Valentina

Le Loibl, Sibyl

Untch, Michael

Schmutzler, Rita K.

机构：

[1] Goethe Univ Frankfurt, German Breast Grp, D-60054 Frankfurt, Germany

[2] Univ Cologne, D-50931 Cologne, Germany

[3] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany

[4] Univ Heidelberg Hosp, Heidelberg, Germany

[5] Hematol Oncol Clin, Munich, Germany

[6] Louisen Hosp, Breast Ctr Duesseldorf, Dusseldorf, Germany

[7] Brustzentrum Sankt Gertrauden Krankenhaus, Berlin, Germany

[8] Frauenklin Gera, Gera, Germany

[9] Sana Kliniken Offenbach, Offenbach, Germany

[10] Univ Rostock, D-18055 Rostock, Germany

[11] Praxisklin Krebsheilkunde, Berlin, Germany

[12] Evangel Huyssens Stiftung, Kliniken Essen Mitte, Breast Canc Ctr, Essen, Germany

[13] Univ Kiel, Kiel, Germany

[14] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-80290 Munich, Germany

[15] German Breast Grp, Neu Isenburg, Germany

[16] Sana Klinikurn Offenbach, German Breast Grp, Neu Isenburg, Germany

[17] Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany

[18] Helios Klinikum Berlin Buch, Multidisciplinary Breast Canc Ctr, Berlin, Germany

[19] Ctr Familial Breast & Ovarian Canc, Cologne, Germany

[20] Ctr Integrated Oncol, Cologne, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1005

引用

页数：1

共 50 条

[41] Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Groheux, David
Ferrer, Loic
Vargas, Jennifer
Martineau, Antoine
Teixeira, Luis
Menu, Philippe
Bertheau, Philippe
Gallinato, Olivier
Colin, Thierry
Lehmann-Che, Jacqueline
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Updated results of neoadjuvant chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 in triple-negative breast cancer (TNBC).
Kern, Peter
Kolberg, Hans C.
Kalisch, Anne
Kimmig, Rainer
Pott, Dirk
Otterbach, Friedrich
Kurbacher, Christian M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
[43] Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
Li, JunJie
Chen, Sheng
Chen, CanMing
Di, GenHong
Liu, GuangYu
Wu, Jiong
Shao, ZhiMin
ONCOTARGET, 2017, 8 (11) : 18399 - 18408
[44] Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations
Hong, Sanghee
Funchain, Pauline
Haddad, Abdo
Crowe, Joseph
Dalpiaz, Nancy
Abraham, Jame
JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (03) : 270 - +
[45] Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy
Kennedy, William R.
Tricarico, Christopher
Gabani, Prashant
Weiner, Ashley A.
Altman, Michael B.
Ochoa, Laura L.
Thomas, Maria A.
Margenthaler, Julie A.
Sanati, Souzan
Peterson, Lindsay L.
Ma, Cynthia X.
Ademuyiwa, Foluso O.
Zoberi, Imran
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (03): : 288 - 296
[46] A predictor of pathological complete response to neoadjuvant chemotherapy in triple -negative breast cancer patients with the DNA repair genes
Huang, Liang
Lang, Guan-Tian
Liu, Qi
Shi, Jin-Xiu
Shao, Zhi-Ming
Cao, A-Yong
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)
[47] Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)
Marhold, Maximilian
Udovica, Simon
Wimmer, Kerstin
Bago-Horvath, Zsuzsanna
Robinson, Tim
Fitzal, Florian
Strasser-Weippl, Kathrin
Bartsch, Rupert
CANCER RESEARCH, 2023, 83 (05)
[48] Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
Masuda, Hiroko
Harano, Kenichi
Miura, Sakiko
Wang, Ying
Hirota, Yuko
Harada, Oi
Jolly, Mohit Kumar
Matsunaga, Yuki
Lim, Bora
Wood, Anita L.
Parinyanitikul, Napa
Lee, Hee Jin
Gong, Gyungyub
George, Jason T.
Levine, Herbert
Lee, Jangsoon
Wang, Xiaoping
Lucci, Anthony
Rao, Arvind
Schweitzer, Brock L.
Lawrence, O. Rayne
Seitz, Robert S.
Morris, Stephan W.
Hout, David R.
Nakamura, Seigo
Krishnamurthy, Savitri
Ueno, Naoto T.
JCO PRECISION ONCOLOGY, 2022, 6
[49] Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer
Van Bockstal, Mieke R.
Noel, Fanchon
Guiot, Yves
Duhoux, Francois P.
Mazzeo, Filomena
Van Marcke, Cedric
Fellah, Latifa
Ledoux, Benjamin
Berliere, Martine
Galant, Christine
ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 49
[50] Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O. Ademuyiwa
Ina Chen
Jingqin Luo
Mothaffar F. Rimawi
Ian S. Hagemann
Bryan Fisk
Gejae Jeffers
Zachary L. Skidmore
Anamika Basu
Megan Richters
Cynthia X. Ma
Katherine Weilbaecher
Jennifer Davis
Rama Suresh
Lindsay L. Peterson
Ron Bose
Nusayba Bagegni
Caron E. Rigden
Ashley Frith
Timothy P. Rearden
Leonel F. Hernandez-Aya
Anna Roshal
Katherine Clifton
Mateusz Opyrchal
Olaronke Akintola-Ogunremi
Byung Ha Lee
Sara Ferrando-Martinez
Sarah E. Church
Meenakshi Anurag
Matthew J. Ellis
Feng Gao
William Gillanders
Obi L. Griffith
Malachi Griffith
Breast Cancer Research and Treatment, 2021, 189 : 187 - 202

← 1 2 3 4 5 →